Our Commitment

- We are committed to help improve access for patients in areas where our therapy is not approved.
- We evaluate requests to determine that the provision of drug will in no way intervene with ongoing clinical trials, regulatory approval or future patient access.
- We support patients who have a serious or life-threatening disease where no other viable standard of care treatment options are available.
- We ensure that the provision of drug in no ways compromises the supply to patients currently on therapy.
- We abide by all local, regional, national and global regulations and laws when permitting access for individual patients.
- We never implement access to unapproved medicines in any country in a way that could be construed as marketing or promotion of a product prior to regulatory approval.

Who We Are

About Us

We are dedicated to bringing innovative medicines to patients with debilitating rare diseases.

Contact Us

To learn more about the program please contact your metreleptin medical representative or go to the Expanded Access Program section of our website, www.novelion.com.

Aegerion Pharmaceuticals
A NOVELION THERAPEUTICS COMPANY

METRELEPTIN EXPANDED ACCESS PROGRAM
One Main Street
Cambridge, MA 02142

METRELEPTIN EXPANDED ACCESS PROGRAM

We have established an Expanded Access Program for metreleptin.

The program has certain clinical eligibility criteria. Patients with lipodystrophy and congenital leptin deficiency (CLD) may be eligible for access to metreleptin if they have no known contraindications to the use of metreleptin (outside of the indication) and they meet the following criteria:

Generalized Lipodystrophy (GL)

- Diagnosis attested to by the treating clinician

Partial Lipodystrophy (PL)

- Established diagnosis of PL,
- Age: ≥ 5 years (children under 5 are reviewed case by case),
- Fasting leptin levels of ≤10 ng/mL (females) and ≤4 ng/mL (males)
- HbA1c ≥8.0% **or** fasting plasma TG ≥ 500 mg/dL
- Patients are receiving maximally tolerated medication for Diabetes Mellitus and High Triglycerides
- No known contraindications to the use of metreletpin

Congenital Leptin Deficiency

- Established diagnosis of CLD
- Leptin levels: below level of detection
- No known contraindications to the use of metreletpin

"Our aim is to be a catalyst of change, easing the burden on these individuals by educating the community, developing transformative therapies and offering comprehensive support for patients living with certain rare diseases.

~Pamela Foulds, MD

Chief Medical Officer, Aegerion

Are you offering the Metreleptin Expanded Access Program in my country?

In order to determine if we are able to provide metreleptin to your patient in your country, please contact your metreleptin medical representative or email us at: customer.services@clinigengroup.com.



How do I apply for the Metreleptin Expanded Access Program?

The Metreleptin Expanded Access Program it is provided through our partnership with the Clinigen Group. If you are interested in enrolling in the Metreleptin Expanded Access Program please reach out to your local metreleptin medical representative.

Applications must be submitted by the HealthCare Professional. Patient eligibility will be determined by Aegerion Pharmaceuticals in accordance with established policies and procedures. The acceptance and processing of this application does not guarantee that access to investigational product will be provided.

If you are approved for the Metreleptin Expanded Access Program, we may follow up with you from time to time to obtain updated information.